Viridian Therapeutics
VRDN | NASDAQ
$29.80
-$1.07 (-3.47%)
At close: Nov 16, 2026, 4:00 PM ET
$29.80
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Viridian Therapeutics Company Profile
Company profile explainedCompany Profile
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Key Executives
| Name | Position |
|---|---|
| Stephen F. Mahoney | Chief Executive Officer, President & Director |
| Jennifer Tousignant | Chief Legal Officer & Corporate Secretary |
| Seth Harmon | Chief Financial Officer |
| Thomas W. Beetham | Chief Operating Officer |
| Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board |
| Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member |
| Melissa Manno | Chief Human Resources Officer |
| Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board |
| Radhika Tripuraneni | Chief Medical Officer |
| Vahe Bedian | Co-Founder & Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 20, 2026 | 4 | Filing |
| Aug 20, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 18, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 07, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
Viridian Therapeutics
| Country | United States |
| IPO Date | Jun 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 252 |
| CEO | Stephen F. Mahoney |
Contact Details
221 Crescent Street Waltham,
Massachusetts 02453 United States
Stock Details
| Ticker Symbol | VRDN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001590750 |
| CUSIP Number | 92790C104 |
| ISIN Number | US92790C1045 |
| SIC Code | 8071 |
Recent News
- 8 days ago / seekingalpha.comViridian Therapeutics, Inc. (VRDN) Discusses VRDN-008 Phase I Results and FcRn Portfolio Development Plans Transcript
- 8 days ago / benzinga.comViridian Therapeutics Stock Rallies on Positive VRDN-008 Trial Results, Eyes 8-Week Dosing
- 8 days ago / businesswire.comViridian Therapeutics Announces Positive VRDN-008 Phase 1 Results Supporting Potential Best-in-Class Profile with Every-8-Week Subcutaneous Dosing
- 10 days ago / businesswire.comViridian Therapeutics to Host Conference Call to Present VRDN-008 Phase 1 Data and FcRn Portfolio Plans on November 9, 2026
- 11 days ago / zacks.comWall Street Analysts Predict a 39.68% Upside in Viridian Therapeutics (VRDN): Here's What You Should Know
- 12 days ago / seekingalpha.comViridian Therapeutics: Strong Start For Lumvoa, VRDN-008 Data Ahead
- 12 days ago / marketbeat.comWhat Viridian Therapeutics (VRDN) Said on Its Q3 Earnings Call
- 13 days ago / seekingalpha.comViridian Therapeutics, Inc. (VRDN) Q3 2026 Earnings Call Transcript
- 13 days ago / zacks.comViridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Beats Revenue Estimates
- 13 days ago / businesswire.comViridian Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Business Progress
Add to Watchlist
Select watchlists to add or remove VRDN